Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.52 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.46 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.45 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CLPP | Q16740 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2346749 | 0.98 | SIGMAR1 (0.50) | SIGMAR1SLC6A5L3MBTL1TMEM97TACR1 | |
| SCHEMBL568477 | 0.98 | SIGMAR1 (0.53) | SIGMAR1SLC6A5L3MBTL1TMEM97CYP1A2 | |
| Hydrochloric Acid SCHEMBL16760314 | 0.95 | SIGMAR1 (0.50) | SIGMAR1SLC6A5L3MBTL1TMEM97CYP1A2 | |
| Hydrogen Peroxide SCHEMBL27308227 | 0.95 | SIGMAR1 (0.50) | SIGMAR1SLC6A5L3MBTL1TMEM97CYP1A2 | |
| SCHEMBL1366467 | 0.93 | L3MBTL1 (0.54) | SIGMAR1SLC6A5L3MBTL1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL31714128 | 0.89 | SLC6A5 (0.57) | SIGMAR1SLC6A5TACR1ACHEMC4R | |
| SCHEMBL1713728 | 0.87 | SIGMAR1 (0.63) | SIGMAR1L3MBTL1TACR1CYP1A2CYP3A4 | |
| SCHEMBL266771 | 0.87 | SLC6A5 (0.59) | SIGMAR1SLC6A5TACR1CLPPACHE | |
| Hydrochloric Acid SCHEMBL1171130 | 0.86 | SIGMAR1 (0.57) | SIGMAR1TACR1ALDH1A1MC4R | |
| SCHEMBL484888 | 0.84 | SIGMAR1 (0.59) | SIGMAR1TACR1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105622444-B | The preparation method of 1- benzyl -3- piperidone hydrochlorides | 重庆威鹏药业有限公司 | 2018-06-01 | — | — | CN | claimed |
| CN-105622444-A | Preparation method for 1-benzyl-3-piperidone hydrochloride | CHONGQING WEIPENG PHARMACEUTICAL CO LTD | 2016-06-01 | — | — | CN | claimed |
| CN-102351783-B | The synthetic method of 1-benzyl-3-piperidone hydrochloride | LI JIANDONG (CN) | 2015-11-18 | — | — | CN | claimed |
| CN-103613531-B | Synthesis method of 1-tert-butylmethoxycarbonyl-3-piperidone | CHEMFUTURE PHARMATECH JIANGSU LTD | 2015-06-17 | — | — | CN | claimed |
| CN-103613531-A | Synthesis method of 1-tert-butylmethoxycarbonyl-3-piperidone | CHEMFUTURE PHARMATECH JIANGSU LTD | 2014-03-05 | — | — | CN | claimed |
| CN-102351783-A | Synthesizing method of 1-benzyl-piperidone hydrochloride | LANZHOU BOC CHEMICAL CO LTD | 2012-02-15 | — | — | CN | claimed |
| US-20250034167-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-01-30 | — | — | US | disclosed |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2025-01-02 | — | — | US | disclosed |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | EPICS THERAPEUTICS (BE) | 2024-09-17 | — | — | US | disclosed |
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | EPICS THERAPEUTICS (BE) | 2024-08-15 | — | — | US | disclosed |
| EP-4384160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-3661923-B1 | N-HETEROCYCLIC COMPOUNDS AS OREXIN 2 AGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-15 | — | — | EP | disclosed |
| CN-117881397-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-04-12 | — | — | CN | disclosed |
| US-4556660-A | ANTIALLERGENS | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-03 | — | — | US | disclosed |
| EP-0099139-A2 | Novel N-(bicyclic heterocyclyl)-4-piperidinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-01-25 | — | — | EP | disclosed |
| US-4332808-A | Dopaminergically stimulating 4-substituted indoles | ROUSSEL UCLAF (FR) | 1982-06-01 | — | — | US | disclosed |
| EP-0001280-B1 | 1-N-ACYLATED-4-O-GLYCOSYL-6-O-GLYCOSYL-1,3-DIAMINOCYCLITOL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SHIONOGI & CO., LTD. (JP) | 1981-11-25 | — | — | EP | disclosed |
| US-4199570-A | AZETIDINE, PYRROLIDINE, OR PIPERIDINE | SHIONOGI & CO., LTD. (JP) | 1980-04-22 | — | — | US | disclosed |
| EP-0001280-A2 | 1-N-acylated-4-O-glycosyl-6-O-glycosyl-1,3-diaminocyclitol derivatives, process for their preparation and pharmaceutical compositions containing them | SHIONOGI & CO., LTD. (JP) | 1979-04-04 | — | — | EP | disclosed |
| US-3939159-A | ANTICONVULSANT, CNS DEPRESSANT | AMERICAN HOECHST CORPORATION (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270716-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | SIGMAR1 1602/4885TACR1 2715/4885ACHE 4422/4885 |
| US-20250002475-A1 | PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS | METTL3, METTL16, DIMT1 | SIGMAR1 1602/4885TACR1 2715/4885ACHE 4422/4885 |
| US-20250034167-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | SIGMAR1 4282/4885TACR1 3695/4885ACHE 4726/4885 |
| US-12091400-B2 | Piperidine derivatives as METTL3 inhibitors | METTL3, METTL16, DIMT1 | SIGMAR1 1602/4885TACR1 2715/4885ACHE 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.